Are natural killer cells the key to treating Epstein-Barr virus–associated lymphoproliferative disorders?
J. Clin. Invest. Michael J. Robertson, et al. 108:801
doi:10.1172/JCI14003 [Go to this article.]

Problems with a PDF?